恶性肿瘤患者术后并发下肢深静脉血栓的预防和护理体会

目的探讨恶性肿瘤患者术后并发下肢深静脉血栓的预防和护理方法。方法采用抗凝，溶栓方法降低血液盘黏稠度和溶解血栓，同时配合手法按摩及相应的宣教。结果18例患者均经积极护理后，分别于症状发生后10～60d的症状消失。结论合理的治疗和正确的护理及及时的入院宣教是治疗恶性肿瘤术后并发下肢深静脉血栓的关键。

恶性肢体骨肿瘤保肢术后运动功能恢复的策略研究

目的采用自拟的四肢恶性肿瘤患者保肢术后运动康复治疗策略,观察运动康复治疗策略对不同保肢术式患者功能恢复的效果。方法选择本院2014年1月至2017年12月实施肢体恶性骨肿瘤保肢手术者47例,按术式分成异体骨移植、自体骨移植、复合重建3组,分别观察各组患者实施运动康复治疗前与后3、6、12个月后,FMA中上下肢部分量表评分结果比较差异。结果异体骨移植组患者治疗3、6个月后,上下肢FMA评分与治疗前比较差异无统计学意义,12个月后上下肢FMA评分与治疗前比较差异有统计学意义(P<0.01),自体骨移植组、复合重建组患者上下肢FMA评分治疗3、6、12个月后均与治疗前比较差异有统计学意义(P<0.01,P<0.001)。结论自拟的四肢恶性肿瘤患者保肢术后运动康复治疗策略有利于提高保肢术患者肢体功能的恢复,且其功能恢复的效果与保肢术式有关。

The choice of the immunosuppressant for the patients of the malignant tumors after kidney transplantation

Objective: To evaluate the efficacy and safety of the immunosuppressant treatment among 10 post-renal transplantation recipients with malignant tumors. Methods: Conversion to sirolimus (SRL) treatment was performed for 10 cases which had found malignant tumors after kidney transplantation. During the follow-up period, the recurrence and diffusion of the tumor, the renal function and rejection were monitored. Results: All these cases despite the death had been followed up for at least 1 year. 9 cases had no recurrence and diffusion. 1 case died due to the tumor diffusion 7 months after the drug conversion. 1 case suffered once acute rejection 2 months after the drug conversion. This acute rejection had been inhibited by flushing dose MP. Conclusion: As a new immunosuppressant, SRL not only can prevent the generation of AR, but inhibit proliferation and development of malignant tumors in kidney transplantation recipients as well.